CDHR2 and neoplasm: They discovered ten genes with acquired mutations; FLT3 and NPM1 were previously described mutations that are thought to contribute to tumour progression, and eight were new mutations present in virtually all tumour cells, which are CDH24 and PCLKC, G-protein-coupled receptors (GPR123 and EBI2), a protein phosphatase (PTPRT), a potential guanine nucleotide exchange factor (KNDC1), a peptide/drug transporter (SLC15A1) and a glutamate receptor gene (GRINL1B).